Grantham, Mayo, Van Otterloo & Co (GMO)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-123,376	Closed	-$14.3M	–	608
2023 Q3	$14.3M	Sell	123,376 -189,535	-61%	-$20.4M	0.07%	222
2023 Q2	$32.2M	Buy	312,911 +97,052	+45%	+$10.2M	0.15%	125
2023 Q1	$23.6M	Buy	215,859 +171,563	+387%	+$19M	0.12%	166
2022 Q4	$5.04M	Buy	+44,296	New	+$3.68M	0.03%	331
2019 Q1	–	Sell	-11,200	Closed	-$219K	–	764
2018 Q4	$219K	Buy	+11,200	New	+$220K	﹤0.01%	506

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s HZNP Position: Q4 2023 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 123,376 shares — an estimated $14.3M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in HZNP in Q4 2018 and held it in 5 quarters. The position peaked at $32.2M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Grantham, Mayo, Van Otterloo & Co (GMO) sold 123,376 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $14.3M.
Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 5 quarters.
Grantham, Mayo, Van Otterloo & Co (GMO)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $32.2M in Q2 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2023, filed 13 Feb 2024.